The study assessed the safety and efficacy of Medicago’s plant-derived vaccine in combination with GlaxoSmithKline’s pandemic adjuvant, an ingredient that boosts immune response and vaccine efficacy, according to The Washington Post.
Brian Ward, medical officer at Medicago, told the Post that plants are used “as bioreactors to produce the antigen” for the vaccine, which the drugmakers are calling “CoVLP.”
The vaccine was 75.3 percent effective against COVID-19 of any severity from the delta variant in the late stage trial, which included 24,000 participants worldwide. The vaccine was well-tolerated and no study participants experienced serious adverse events, the drugmakers said. The trial did not assess the vaccine’s efficacy against the omicron variant.
Medicago said it initiated the regulatory filing process for the vaccine with the FDA.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
